Table 1

The future of incretin-based therapies

Role of GLP-1 in obesity?
GLP-1 in prediabetes?
GLP-1 in type 1 diabetes?
GLP-1 and pediatric indications in type 1 diabetes and T2D?
GLP-1 action in neuroprotection and neurodegeneration
Therapeutic potential of GLP-1 in diseases of inflammation?
GLP-1 and fatty liver disease—therapeutic potential and MOA?
Cardiovascular indications and MOA?
GLP-1, oxidative stress, and microvascular diseases in nerves, eyes, and kidney?
Coagonists? Triagonists? Insulin combinations?
Safety of GLP-1 therapies—inflammation, cancer, and cardiovascular events?
  • MOA, mechanism of action; T2D, type 2 diabetes.